TickerHumSide-by-side comparison
Regeneron Pharmaceuticals vs Vertex Pharmaceuticals
As of Nov 11, 2026, P/E is 20.3x for Regeneron Pharmaceuticals vs 34.7x for Vertex Pharmaceuticals; revenue growth is 18.6% for Regeneron Pharmaceuticals vs 10.5% for Vertex Pharmaceuticals; operating margin is 28.8% for Regeneron Pharmaceuticals vs 33.2% for Vertex Pharmaceuticals; net margin is 28.5% for Regeneron Pharmaceuticals vs 30.7% for Vertex Pharmaceuticals.
What stands out
- Regeneron Pharmaceuticals is cheaper on earnings: 20.3x P/E vs 34.7x for Vertex Pharmaceuticals.
- Regeneron Pharmaceuticals carries less debt relative to equity: 0.06 vs 0.17 for Vertex Pharmaceuticals.
Key metrics
| Metric | REGN | VRTX |
|---|---|---|
| Price | $916.82 | $538.82 |
| Market cap | — | $136.61B |
| P/E | 20.3x (#1) | 34.7x (#2) |
| P/S | — | 10.5x (#1) |
| Revenue growth | 18.6% (#1) | 10.5% (#2) |
| Operating margin | 28.8% (#2) | 33.2% (#1) |
| Net margin | 28.5% (#2) | 30.7% (#1) |
| Debt / equity | 0.06 (#1) | 0.17 (#2) |
| 1-year return | +34.5% (#1) | +24.1% (#2) |
| Research score | 78/100 (#1) | 71/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Regeneron Pharmaceuticals, Inc. (REGN) — Biotechnology
- Vertex Pharmaceuticals Incorporated (VRTX) — Biotechnology